Córdoba, December 12nd 2015. VivaCell is proud to announce that last week the Spanish Society for Cannabinoid Research (SEIC) awarded Dr. Carmen Navarrete, Project Manager at VivaCell Biotechnology España, in the 2014 XV Annual Meeting. SEIC prizes to the best communications and posters are given annually to recognize outstanding work in basic or clinic research in cannabinoids.
The work is entitled A novel cannabidiol derivative induces polarization of M2 machrophages, HIF-1 stabilization and alleviates neuroinflammation in different models of Multiple Sclerosis. This study described the effect of novel non-electrophilic CBD quinol-derivatives in two different murine models of MS, revealing a diminution of demyelization and axonal damage. The results highlight the therapeutic potential of new CBD derivatives for the treatment of neuroinflammatory diseases such as multiple sclerosis.
This successful work results from the collaboration between VivaCell Biotechnology España and the Cajal Institute of CSIC (Neuroimmunology Group, Madrid, Spain), IMIBIC (University of Córdoba and University Hospital Queen Sofía; Córdoba, Spain), and the University of Freiburg (Neurochemistry Research Group, Medical School, Freiburg, Germany).
About VivaCell Biotechnology Spain SL
Founded in 2003 in Cordoba (Spain), VivaCell is a private pharmaceutical company specializing in the development of natural products, especially phytocannabinoids derivatives for the treatment of inflammatory and neurodegenerative diseases.
Project funded by INNPACTO Ref. IPT-2011-0861-900000, Ministerio de Ciencia e Innovación, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica, 2008-2011, and European Union, Regional Development European Funds.